To bring a new drug to market costs on average $1.3 billion, according to a recent report in the Journal of the American Medical Association, and takes up to 20 years. Read...
Read MorePRESS RELEASE — , the leading provider of quantum control solutions that accelerate the realization of practical quantum computers, and Oxford Instruments, a leading provider of cryogenic systems, announced today a new partnership that will make Quantum Machines’ products available for purchase through Oxford Instruments sales channels. This collaboration will allow customers working on superconducting and spin qubit systems to purchase all required components from one vendor. Read more...
Read MoreIQM Quantum Computers has developed a commercially available on-site quantum computer, the IQM Spark prototype, which uses superconducting technology. This system is designed to provide low-barrier access to both its hardware and software components, making it suitable for educational and research purposes. The system can be used to teach quantum concepts, deepen understanding of quantum theory and quantum computing, and replicate recent research achievements. The hardware includes a superconducting quantum processing unit, a dilution refrigerator, and control electronics. The software allows for direct manipulation of the qubits or running small scale quantum algorithms. Read...
Read MoreFrench regulators recently warned that a January 2024 cyber-attack on two major healthcare sector companies caused over 33 million people’s data to be compromised. The data includes sensitive personal information, which threat actors could exploit in phishing campaigns and financial fraud schemes. Cybersixgill observed demand for the stolen data on the underground, in addition to threat actors disseminating similar content from previous breaches. Read more...
Read MoreVANCOUVER, British Columbia–(BUSINESS WIRE)–SaNOtize Research & Development Corp., a therapeutics technology company based in Vancouver, BC, announced today the start of a Phase 2 safety and efficacy trial of its novel Nitric Oxide Nasal Spray (NONS) for the treatment of recurrent acute rhinosinusitis (RARS). Read more...
Read More
